Natalizumab Biosimilar to Get FDA Review for MS, Crohn Disease Indications
The application is under review for relapsing forms of multiple sclerosis and Crohn disease.
Multiple Sclerosis
June 2022 Recap: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
COVID-19 Linked to Increased Risk of Neurological Disorders
Most neurological disorders do not appear to be more frequent after COVID-19 than after influenza or bacterial pneumonia
Cannabis-Derived Oromucosal Spray Misses in MS Spasticity Trial
The RELEASE MSS1 trial included adults with a confirmed diagnosis of any disease subtype of multiple sclerosis.
Lyvispah Now Available for Spasticity Due to MS, Other Spinal Cord Disorders
The approval was based upon a bioavailability study in healthy adults comparing baclofen oral tablets to Lyvispah.
FDA Changes Decision Date for Investigational MS Drug Ublituximab
The FDA extended the action date to allow time to review a submission provided by the Company.
FDA Clears Cionic Neural Sleeve for Patients With Mobility Issues
The Cionic Neural Sleeve is the first product to combine movement analysis and augmentation into a wearable garment.
Fleqsuvy Approved for Spasticity Due to Multiple Sclerosis
The approval was based a bioavailability study comparing baclofen oral tablets with Fleqsuvy.
Purified Cortrophin Gel Now Available for Certain Chronic Autoimmune Disorders
The product is available through a network of specialty pharmacies and distributors.
Epstein-Barr Virus Suspected as Cause of Multiple Sclerosis
Risk for MS increased 32-fold following EBV infection, but not following infection with other viruses, including cytomegalovirus
